Hallmarks of alternative splicing in cancer

[1]  S. Knapp,et al.  Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. , 2013, Investigative ophthalmology & visual science.

[2]  A. Krainer,et al.  Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. , 2013, Molecular cell.

[3]  F. Rousset,et al.  RBFOX2 Is an Important Regulator of Mesenchymal Tissue-Specific Splicing in both Normal and Cancer Tissues , 2012, Molecular and Cellular Biology.

[4]  Claude C. Warzecha,et al.  Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). , 2012, Seminars in cancer biology.

[5]  Chonghui Cheng,et al.  Snail Represses the Splicing Regulator Epithelial Splicing Regulatory Protein 1 to Promote Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[6]  Ryan M. Plocinik,et al.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. , 2012, Molecular cell.

[7]  X. Tian,et al.  Quantification of Alternative Splicing Variants of Human Telomerase Reverse Transcriptase and Correlations with Telomerase Activity in Lung Cancer , 2012, PloS one.

[8]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[9]  C. Chalfant,et al.  The Proto-oncogene PKCι Regulates the Alternative Splicing of Bcl-x Pre-mRNA , 2012, Molecular Cancer Research.

[10]  A. Krainer,et al.  Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. , 2012, Cell reports.

[11]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[12]  A. Krainer,et al.  THE SPLICING FACTOR SRSF1 REGULATES APOPTOSIS AND PROLIFERATION TO PROMOTE MAMMARY EPITHELIAL CELL TRANSFORMATION , 2011, Nature Structural &Molecular Biology.

[13]  P. Govitrapong,et al.  Emetine regulates the alternative splicing of caspase 9 in tumor cells. , 2011, Oncology letters.

[14]  K. Miyazono,et al.  TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP , 2011, Oncogene.

[15]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[16]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[17]  Naoko Okumura,et al.  Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. , 2011, Biochemical and biophysical research communications.

[18]  G. Lizée,et al.  Natural Splice Variant of MHC Class I Cytoplasmic Tail Enhances Dendritic Cell-Induced CD8+ T-Cell Responses and Boosts Anti-Tumor Immunity , 2011, PloS one.

[19]  Nicholas C. Flytzanis,et al.  An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.

[20]  D. Wong,et al.  Exon 11 Skipping of E-Cadherin RNA Downregulates Its Expression in Head and Neck Cancer Cells , 2011, Molecular Cancer Therapeutics.

[21]  Amy J. Hawkins,et al.  SRSF1 Regulates the Alternative Splicing of Caspase 9 Via A Novel Intronic Splicing Enhancer Affecting the Chemotherapeutic Sensitivity of Non–Small Cell Lung Cancer Cells , 2011, Molecular Cancer Research.

[22]  Jianren Gu,et al.  Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. , 2011, Neoplasia.

[23]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[24]  A. Lengeling,et al.  Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1 , 2011, Proceedings of the National Academy of Sciences.

[25]  Christine J. Martin,et al.  Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. , 2011, Chemical science.

[26]  Amy J. Hawkins,et al.  Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. , 2010, Cancer research.

[27]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[28]  G. Dambrine,et al.  Alternative splicing and nonsense-mediated decay regulate telomerase reverse transcriptase (TERT) expression during virus-induced lymphomagenesis in vivo , 2010, BMC Cancer.

[29]  Adrian R. Krainer,et al.  Alternative Splicing of SLC39A14 in Colorectal Cancer is Regulated by the Wnt Pathway* , 2010, Molecular & Cellular Proteomics.

[30]  Yi Xing,et al.  An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition , 2010, The EMBO journal.

[31]  S. Harper,et al.  Balance of pro‐ versus anti‐angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth , 2010, The Journal of pathology.

[32]  E. Brambilla,et al.  The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo , 2010, Oncogene.

[33]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[34]  T. Hyslop,et al.  Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. , 2010, Cancer research.

[35]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[36]  K. Al-Kuraya,et al.  Prognostic significance of alterations in KRAS isoforms KRAS‐4A/4B and KRAS mutations in colorectal carcinoma , 2009, The Journal of pathology.

[37]  M. Ladomery,et al.  Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms , 2009, The Journal of Biological Chemistry.

[38]  P. Jordan,et al.  Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. , 2009, Human molecular genetics.

[39]  Sherif Abou Elela,et al.  Cancer-associated regulation of alternative splicing , 2009, Nature Structural &Molecular Biology.

[40]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[41]  H. Chung,et al.  Changes of telomerase activity by alternative splicing of full-length and beta variants of hTERT in breast cancer patients. , 2009, Oncology research.

[42]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[43]  M. Sitbon,et al.  Protection against Retrovirus Pathogenesis by SR Protein Inhibitors , 2009, PloS one.

[44]  X. Geng,et al.  Changes of the Alternative Splicing Variants of Human Telomerase Reverse Transcriptase during Gastric Carcinogenesis , 2008, Pathobiology.

[45]  C. Ghigna,et al.  Alternative Splicing and Tumor Progression , 2008, Current genomics.

[46]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[47]  M. Ladomery,et al.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors , 2008, Journal of Cell Science.

[48]  J. Valcárcel,et al.  RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. , 2008, Molecular cell.

[49]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[50]  L. Corcos,et al.  E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35 , 2008, Cell Death and Differentiation.

[51]  J. García,et al.  p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis , 2008, International journal of cancer.

[52]  C. Grosskreutz,et al.  Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma , 2008, Molecular vision.

[53]  L. Shkreta,et al.  Antagonistic Effects of the SRp30c Protein and Cryptic 5 ′ Splice Sites on the Alternative Splicing of the Apoptotic Regulator Bcl-x* , 2008, Journal of Biological Chemistry.

[54]  P. Febbo,et al.  Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo , 2008, Clinical & Experimental Metastasis.

[55]  Sherif Abou Elela,et al.  Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes , 2008, Molecular Cancer Therapeutics.

[56]  S. Friedman,et al.  Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. , 2008, Gastroenterology.

[57]  J. Cáceres,et al.  The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. , 2008, Molecular cell.

[58]  B. Gallie,et al.  Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression , 2008, Human mutation.

[59]  S. Harper,et al.  VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy , 2008, British Journal of Cancer.

[60]  E. Kleinerman,et al.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice , 2008, British Journal of Cancer.

[61]  J. Scheiber,et al.  Alternative splicing of TGF-betas and their high-affinity receptors TβRI, TβRII and TβRIII (betaglycan) reveal new variants in human prostatic cells , 2007, BMC Genomics.

[62]  D. Bates,et al.  Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma , 2007, British Journal of Cancer.

[63]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[64]  F. Eitner,et al.  Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[65]  M. Dewhirst,et al.  Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity , 2006, Proceedings of the National Academy of Sciences.

[66]  M. Hagiwara,et al.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Sharp,et al.  A positive feedback loop couples Ras activation and CD44 alternative splicing. , 2006, Genes & development.

[68]  M. Garcia-Blanco,et al.  Fox-2 Mediates Epithelial Cell-Specific Fibroblast Growth Factor Receptor 2 Exon Choice , 2006, Molecular and Cellular Biology.

[69]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[70]  N. Rouas-Freiss,et al.  Switch of HLA‐G alternative splicing in a melanoma cell line causes loss of HLA‐G1 expression and sensitivity to NK lysis , 2005, International journal of cancer.

[71]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[72]  A. Krainer,et al.  Involvement of SR proteins in mRNA surveillance. , 2004, Molecular cell.

[73]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[74]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[75]  N. Gray,et al.  A novel role for shuttling SR proteins in mRNA translation. , 2004, Genes & development.

[76]  E. Wagner,et al.  A Stem Structure in Fibroblast Growth Factor Receptor 2 Transcripts Mediates Cell-Type-Specific Splicing by Approximating Intronic Control Elements , 2003, Molecular and Cellular Biology.

[77]  J. Steitz,et al.  SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. , 2003, Molecular cell.

[78]  D. Gillatt,et al.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.

[79]  Kenshi Hayashi,et al.  Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. , 2002, Blood.

[80]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[81]  Russ P. Carstens,et al.  An Intronic Splicing Silencer Causes Skipping of the IIIb Exon of Fibroblast Growth Factor Receptor 2 through Involvement of Polypyrimidine Tract Binding Protein , 2000, Molecular and Cellular Biology.

[82]  D. Lohmann.  RB1 gene mutations in retinoblastoma , 1999, Human mutation.

[83]  P. Leder,et al.  WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  John Calvin Reed,et al.  Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. , 1996, Cancer research.

[85]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[86]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[87]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[88]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[89]  G. Viglietto,et al.  Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. , 1993, Oncogene.

[90]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[91]  D. Burk,et al.  On respiratory impairment in cancer cells. , 1956, Science.

[92]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[93]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[94]  J. Ambati,et al.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth , 2009 .

[95]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[96]  Ö. Türeci,et al.  Multiple Splice Variants of Lactate Dehydrogenase C Selectively Expressed in Human Cancer 1 , 2 , 2002 .

[97]  W. Wood,et al.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. , 1996, Proceedings of the National Academy of Sciences of the United States of America.